• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

多发性骨髓瘤原发性细胞遗传学异常的种族差异:一项多中心研究。

Racial differences in primary cytogenetic abnormalities in multiple myeloma: a multi-center study.

作者信息

Greenberg A J, Philip S, Paner A, Velinova S, Badros A, Catchatourian R, Ketterling R, Kyle R A, Kumar S, Vachon C M, Rajkumar S V

机构信息

Department of Medicine, Division of Hematology, Mayo Clinic, Rochester, MN, USA.

University of Maryland, Baltimore, MD, USA.

出版信息

Blood Cancer J. 2015 Jan 2;5(1):e271. doi: 10.1038/bcj.2014.91.

DOI:10.1038/bcj.2014.91
PMID:25555162
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5404218/
Abstract

We examined four clinically assessed cytogenetic subtypes (t(11;14), t(4;14), monosomy 13/del13q and monosomy 17/del17p in 292 black patients with newly diagnosed multiple myeloma (MM) from four medical centers, who had fluorescent in situ hybridization testing results available in their medical records. We then compared the prevalence of these abnormalities with a previously characterized Mayo Clinic cohort of 471 patients with MM. We found a significant difference in the prevalence of the t(11;14) immunoglobulin heavy chain (IgH) translocation between blacks and whites, 6.5% versus 17.6%, respectively, P<0.0001. Blacks also had lower rates of the t(4;14) IgH translocation, (5.5% versus 10%); monosomy 13/del13q (29.1 versus 49.3%); and monosomy 17/del17p (7.9% versus 13%). Consequently, 63.4% of blacks versus 34.6% of whites did not have any of the four abnormalities that we studied, P<0.001. As almost all MM is associated with either an IgH translocation or trisomies, we hypothesize that MM in blacks is associated with either excess prevalence of either the trisomic (hyperdiploid) form of MM or an IgH translocation besides t(11;14) or t(4;14). We conclude that there are significant differences in the cytogenetic subtypes of MM that occur in blacks and whites.

摘要

我们检测了来自四个医疗中心的292例新诊断的黑人多发性骨髓瘤(MM)患者的四种经临床评估的细胞遗传学亚型(t(11;14)、t(4;14)、13号染色体单体/13q缺失和17号染色体单体/17p缺失),这些患者的病历中有荧光原位杂交检测结果。然后,我们将这些异常的患病率与之前在梅奥诊所确定特征的471例MM患者队列进行了比较。我们发现,黑人与白人之间t(11;14)免疫球蛋白重链(IgH)易位的患病率存在显著差异,分别为6.5%和17.6%,P<0.0001。黑人中t(4;14) IgH易位的发生率也较低(5.5%对10%);13号染色体单体/13q缺失(29.1%对49.3%);以及17号染色体单体/17p缺失(7.9%对13%)。因此,63.4%的黑人与34.6%的白人没有我们所研究的四种异常中的任何一种,P<0.001。由于几乎所有的MM都与IgH易位或三体性相关,我们推测黑人的MM与MM的三体(超二倍体)形式的患病率过高或除t(11;14)或t(4;14)之外的IgH易位有关。我们得出结论,黑人和白人中发生的MM细胞遗传学亚型存在显著差异。

相似文献

1
Racial differences in primary cytogenetic abnormalities in multiple myeloma: a multi-center study.多发性骨髓瘤原发性细胞遗传学异常的种族差异:一项多中心研究。
Blood Cancer J. 2015 Jan 2;5(1):e271. doi: 10.1038/bcj.2014.91.
2
The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma.复发性免疫球蛋白重链(IgH)易位与非超二倍体变异型多发性骨髓瘤高度相关。
Blood. 2003 Oct 1;102(7):2562-7. doi: 10.1182/blood-2003-02-0493. Epub 2003 Jun 12.
3
Cytogenetics of multiple myeloma: interpretation of fluorescence in situ hybridization results.多发性骨髓瘤的细胞遗传学:荧光原位杂交结果解读
Br J Haematol. 2003 Mar;120(6):944-52. doi: 10.1046/j.1365-2141.2003.04172.x.
4
Timing of acquisition of deletion 13 in plasma cell dyscrasias is dependent on genetic context.浆细胞异常增生中缺失 13 获得的时间取决于遗传背景。
Haematologica. 2009 Dec;94(12):1708-13. doi: 10.3324/haematol.2009.011064.
5
Cytogenetic Abnormalities in Multiple Myeloma Patients at a Tertiary Healthcare Center in India.印度一家三级医疗中心多发性骨髓瘤患者的细胞遗传学异常
Asian Pac J Cancer Prev. 2019 Jan 25;20(1):235-241. doi: 10.31557/APJCP.2019.20.1.235.
6
The Ig heavy chain gene is frequently involved in chromosomal translocations in multiple myeloma and plasma cell leukemia as detected by in situ hybridization.通过原位杂交检测发现,免疫球蛋白重链基因在多发性骨髓瘤和浆细胞白血病中常参与染色体易位。
Blood. 1997 Jul 15;90(2):526-34.
7
Negative prognostic significance of two or more cytogenetic abnormalities in multiple myeloma patients treated with autologous stem cell transplantation.自体造血干细胞移植治疗多发性骨髓瘤患者中两种或多种细胞遗传学异常具有负预后意义。
Neoplasma. 2010;57(2):111-7. doi: 10.4149/neo_2010_02_111.
8
Molecular cytogenetic aberrations in patients with multiple myeloma studied by interphase fluorescence in situ hybridization.采用间期荧光原位杂交技术研究多发性骨髓瘤患者的分子细胞遗传学畸变。
Exp Oncol. 2007 Jun;29(2):116-20.
9
[Correlation of chromosomal aberrations with prognostic markers in multiple myeloma patients--a single institution study].[多发性骨髓瘤患者染色体畸变与预后标志物的相关性——一项单机构研究]
Korean J Lab Med. 2008 Dec;28(6):413-8. doi: 10.3343/kjlm.2008.28.6.413.
10
Monosomy 13 is associated with the transition of monoclonal gammopathy of undetermined significance to multiple myeloma. Intergroupe Francophone du Myélome.13号染色体单体与意义未明的单克隆丙种球蛋白病向多发性骨髓瘤的转变相关。法语国家骨髓瘤研究组。
Blood. 1999 Oct 15;94(8):2583-9.

引用本文的文献

1
Monoclonal Gammopathies in Africa.非洲的单克隆丙种球蛋白病
Clin Lymphoma Myeloma Leuk. 2025 May 31. doi: 10.1016/j.clml.2025.05.023.
2
Population differences in the associations between chromosomal abnormalities and overall survival of multiple myeloma.染色体异常与多发性骨髓瘤总生存期之间关联的人群差异。
Blood Neoplasia. 2024 Dec 26;2(1):100065. doi: 10.1016/j.bneo.2024.100065. eCollection 2025 Feb.
3
Cancer statistics for African American and Black people, 2025.2025年非裔美国人和黑人的癌症统计数据。
CA Cancer J Clin. 2025 Mar-Apr;75(2):111-140. doi: 10.3322/caac.21874. Epub 2025 Feb 20.
4
Racial differences as predictors of outcomes in young patients with multiple myeloma.种族差异作为年轻多发性骨髓瘤患者预后的预测因素
Blood Cancer J. 2022 Jul 27;12(7):114. doi: 10.1038/s41408-022-00708-3.
5
Socioeconomic Status is Globally a Prognostic Factor for Overall Survival of Multiple Myeloma Patients: Synthesis of Studies and Review of the Literature.社会经济地位在全球范围内是多发性骨髓瘤患者总生存期的一个预后因素:研究综述与文献回顾
Mediterr J Hematol Infect Dis. 2021 Jan 1;13(1):e2021006. doi: 10.4084/MJHID.2021.006. eCollection 2021.
6
Racial differences in treatment and outcomes in multiple myeloma: a multiple myeloma research foundation analysis.多发性骨髓瘤治疗和结局的种族差异:多发性骨髓瘤研究基金会分析。
Blood Cancer J. 2020 Aug 7;10(8):80. doi: 10.1038/s41408-020-00347-6.
7
Dissecting racial disparities in multiple myeloma.剖析多发性骨髓瘤中的种族差异。
Blood Cancer J. 2020 Feb 17;10(2):19. doi: 10.1038/s41408-020-0284-7.
8
Racial disparities, cancer and response to oxidative stress.种族差异、癌症与对氧化应激的反应。
Adv Cancer Res. 2019;144:343-383. doi: 10.1016/bs.acr.2019.03.012. Epub 2019 Apr 23.
9
Cytogenetic Abnormalities in Multiple Myeloma Patients at a Tertiary Healthcare Center in India.印度一家三级医疗中心多发性骨髓瘤患者的细胞遗传学异常
Asian Pac J Cancer Prev. 2019 Jan 25;20(1):235-241. doi: 10.31557/APJCP.2019.20.1.235.
10
Biological determinants of health disparities in multiple myeloma.多发性骨髓瘤健康差异的生物学决定因素。
Blood Cancer J. 2018 Aug 28;8(9):85. doi: 10.1038/s41408-018-0118-z.

本文引用的文献

1
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.国际骨髓瘤工作组更新了多发性骨髓瘤的诊断标准。
Lancet Oncol. 2014 Nov;15(12):e538-48. doi: 10.1016/S1470-2045(14)70442-5. Epub 2014 Oct 26.
2
Multiple myeloma: 2014 Update on diagnosis, risk-stratification, and management.多发性骨髓瘤:2014 年诊断、风险分层和治疗更新。
Am J Hematol. 2014 Oct;89(10):999-1009. doi: 10.1002/ajh.23810.
3
Racial disparities in the prevalence of monoclonal gammopathies: a population-based study of 12,482 persons from the National Health and Nutritional Examination Survey.单克隆丙种球蛋白病患病率的种族差异:一项基于美国国家健康与营养检查调查中12482人的人群研究。
Leukemia. 2014 Jul;28(7):1537-42. doi: 10.1038/leu.2014.34. Epub 2014 Jan 20.
4
Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma.泊马度胺:一种用于治疗多发性骨髓瘤的新型免疫调节药物。
Blood Cancer J. 2013 Sep 6;3(9):e143. doi: 10.1038/bcj.2013.38.
5
Relationship between initial clinical presentation and the molecular cytogenetic classification of myeloma.骨髓瘤的初始临床表现与分子细胞遗传学分类之间的关系。
Leukemia. 2014 Feb;28(2):398-403. doi: 10.1038/leu.2013.258. Epub 2013 Sep 5.
6
Uncovering the biology of multiple myeloma among African Americans: a comprehensive genomics approach.揭示非裔美国人多发性骨髓瘤的生物学机制:一种综合基因组学方法。
Blood. 2013 Apr 18;121(16):3147-52. doi: 10.1182/blood-2012-07-443606. Epub 2013 Feb 19.
7
The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapies.治疗性人源CD38抗体达雷妥尤单抗可增强新出现的多种药物疗法的抗骨髓瘤效果。
Blood Cancer J. 2011 Oct;1(10):e41. doi: 10.1038/bcj.2011.42. Epub 2011 Oct 28.
8
Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics.多发性骨髓瘤中的三体:对高危细胞遗传学患者生存的影响。
Blood. 2012 Mar 1;119(9):2100-5. doi: 10.1182/blood-2011-11-390658. Epub 2012 Jan 10.
9
Disparities in the prevalence, pathogenesis and progression of monoclonal gammopathy of undetermined significance and multiple myeloma between blacks and whites.黑人与白人之间意义未明的单克隆丙种球蛋白病和多发性骨髓瘤的流行率、发病机制和进展的差异。
Leukemia. 2012 Apr;26(4):609-14. doi: 10.1038/leu.2011.368. Epub 2011 Dec 23.
10
Racial disparities in incidence and outcome in multiple myeloma: a population-based study.多发性骨髓瘤发病和转归的种族差异:一项基于人群的研究。
Blood. 2010 Dec 16;116(25):5501-6. doi: 10.1182/blood-2010-07-298760. Epub 2010 Sep 7.